Newsletter – Q1 2026
Mar 18, 2026
Welcome to the 1st edition
Welcome to the inaugural issue of Complete Genomics Quarterly, ourbrand-new newsletter launching today! We’re thrilled to bring you a curated update each quarter—packed with product features, reagent insights, upcoming events, and more.
Thank you for joining us. We hope this newsletter keeps you informed, inspired, and engaged with the exciting developments happening at Complete Genomics.
Our Mission
At Complete Genomics, our mission is simple yet powerful: to drive genomics forward with complete sequencing solutions that improve lives . As a pioneering global life-science company since 2005, we deliver end-to-end platforms, from sample prep and lab automation to ultra-accurate DNBSEQ instruments and streamlined data analysis. We’re committed to making genomics accessible, affordable, and reliable, empowering researchers and clinicians to tackle pressing scientific and medical challenges.
Featured Stories
New Chapter – Complete Genomics to be Acquired by Swiss Rockets.
Complete Genomics has announced that it has entered into a definitive agreement to be acquired by Swiss Rockets AG, a Switzerland-based life sciences group focused on precision medicine and biotechnology innovation. The transaction is expected to support the continued growth of Complete Genomics by strengthening its innovation pipeline and expanding global manufacturing capabilities.
Under the agreement, Swiss Rockets will acquire 100% ownership of Complete Genomics upon closing. The company will continue to operate as a U.S.-based organization, with its existing teams maintaining responsibility for product strategy, software development, and customer support. Importantly, customers can expect no disruption to products, services, or existing agreements as operations continue as usual. The partnership brings together Complete Genomics’ expertise in next-generation sequencing technologies with Swiss Rockets’ focus on precision medicine, oncology, and advanced therapeutics. Together, the companies aim to accelerate innovation in genomics and expand access to technologies that support the development of new diagnostics, therapies, and precision health solutions worldwide.
AGBT 2026 Recap
Complete Genomics has been advancing sequencing innovation for more than 20 years, delivering high accuracy whole genome sequencing through our proprietary DNBSEQ technology and CoolMPS chemistry. These platforms support research, clinical, and population scale programs with consistent data quality and scalability.
At AGBT, we unveiled the DNBSEQ-T7+ system, a multi-flowcell PE150 platform built for high-throughput genome programs and compatible with parallel spatial applications. We also introduced our CoolMPS chemistry, designed to combine the economics of short read sequencing with insights typically associated with long read approaches. We recently entered an agreement to join Swiss Rockets AG, strengthening long-term capital backing while maintaining US operations and continuity in leadership and platform development. What an exciting time here at CG!
Bronze 2 Workshop Highlight:
Dr. Yuxuan Wang from Johns Hopkins is an early-access user of the DNBSEQ-T7+. Dr. Wang shared compelling data on the use of DNBSEQ technology for liquid biopsy and methylation patterns in cellfree DNA to monitor immunotherapy toxicity. The session reinforced how high-quality, low-cost sequencing is making scalable oncology and precision monitoring a clinical reality.
Morning Presentations Highlight:
Prof. Khashayarsha Khazaie from Mayo Clinic showed new data on mapping disease microenvironments in endometriosis and colorectal cancer using Stereo-seq FF and Stereo-seq OMNI for FFPE. The latest Stereo-seq OMNI assay delivers true single-cell total RNA profiling, with a combinatorial probe design that efficiently captures both coding and non-coding transcripts.
Technology & Product Updates
DNBSEQ-T7+
The DNBSEQ-T7+ is the most powerful ultrahigh-throughput sequencer available today. With extreme daily output of over 14 Tb in 24 hours, true multi-omics flexibility through independently controlled flow cells, and economics at scale enabled by DNBSEQ technology, it delivers Q40 accuracy without the tradeoffs typical of other high-throughput platforms.
Power Through Your Sequencing Projects
With a daily output over 14 Tb, DNBSEQ-T7+ can generate up to 35,000 whole human genomes sequencing (WGS)* per year. From library loading through DNA nanoball (DNB) generation, sequencing, and post-run washing, the entire workflow is completed within 24 hours. Technology & Product Updates: DNBSEQ-T7+ FASTQ files are generated while sequencing is in progress, allowing the next run to begin immediately. The system is fully automated, enabling walk-away operation after loading and minimal hands-on time between runs.
Run Multi-Omics Research on One Platform
DNBSEQ-T7+ is equipped with four independently controlled flow cells, allowing each to be run separately or in parallel. No other ultra-high-throughput sequencer combines this level of scale and flexibility in a single platform. This unique architecture makes DNBSEQ-T7+ ideal for both large-genome projects and multiomics research, enabling WGS, WGMS, single-cell, and spatial transcriptomics to be run on the same instrument.
Stereo-seq Omni for FFPE Solution V 1.1
The Stereo-seq OMNI for FFPE Solution v1.1 expands the power of spatial transcriptomics to one of the most widely used sample types in research and clinical studies, formalin-fixed paraffin embedded (FFPE) tissue. The solution enables researchers to recover rich spatial gene expression information from archived samples while preserving the spatial context of the tissue. Version 1.1 introduces improvements in RNA capture efficiency and workflow performance, enabling more reliable data generation from challenging FFPE samples.
Optimized for partially degraded RNA and compatible with samples with DV200 values above 30%, the solution allows researchers to unlock valuable insights from retrospective tissue collections. Built on the Stereo-seq platform, the OMNI FFPE workflow provides high-resolution spatial transcriptomic profiling across large tissue areas, helping researchers better understand tissue organization, disease biology, and cellular interactions.
Application Highlights
Insights from the Bronze 2 Workshop: The Future of ctDNA in Clinical Oncology.
It was a privilege to host Yuxuan Wang, MD, PhD, at Johns Hopkins Medicine, one of our DNBSEQ-T7+ early-access customers, for a deep dive into the use of DNBSEQ sequencing technology for oncology applications using circulating tumor DNA (ctDNA). The session highlighted how ctDNA is transitioning from a research tool to a vital clinical marker for minimal residual disease (MRD) and early cancer detection.
Key Takeaways:
- Scalable Oncology: DNBSEQ technology, delivering high accuracy at a low cost ($100 per genome)—presents an ideal option for large-volume oncology sequencing and clinical testing.
- Precision Monitoring: Dr. Wang discussed how tissue-specific methylation patterns in cell-free DNA can identify treatment toxicity early in patients receiving immunotherapy.
- Excellent data quality: Methylation testing can reveal organ damage during treatment; preliminary data on the DNBSEQ-T7+ demonstrated exceptional performance with high Q40 scores and 14B reads.
Thank you, Dr. Wang, for sharing such impactful research with our community!
Complete Genomics is proud to be part of the innovations improving the lives of cancer patients.
Research Spotlight
New on the Complete Genomics Blog
Cells may look similar, but their molecular stories are vastly different.
Our newest blog explores how Complete Genomics’ DNBSEQ technology enables researchers to decode cellular diversity through powerful single-cell RNA sequencing workflows.
From improved data accuracy to scalable sequencing performance, learn how our technology is helping scientists reveal the hidden complexity of tissues, diseases, and biological systems.
Dive into the blog and see what’s possible at the single-cell level.
Customer & Community highlights
We want to welcome 2 new CSP’s to the CG family
Mayo Clinic, Arizona
Platform: DNBSEQ-T7
We also want to highlight JHU’s newly added T7+
Vancouver Prostate Centre
Platforms: DNBSEQ-G400, DNBSEQ-T7
Upcoming Events
We’d love to meet you in person! Visit us at these upcoming conferences:
National Events
|
Date |
Event |
|---|---|
|
April 12-April 15, 2026 |
|
|
April 17-April 22, 2026 |
|
|
June 4-June 8, 2026 |
Local Events
|
Date |
Event |
|---|---|
|
April 12-April 15, 2026 |
event page |
|
April 17-April 22, 2026 |
event page |
Stay tuned for registration info, presentation schedules, and exclusive networking invites.
Want to schedule a meeting with our team at one of these events? Contact us!
For more events, please check our events page.
What’s Next?
Coming in Q4:
- A closer look at the T1+ instrument
- A spotlight on a new publication powered by our sequencing platforms
Subscribe for exclusive content and expert insights.
